Antiplatelet therapy regimen

This page covers all Antiplatelet therapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12 receptor and cyclooxygenase (COX).

Targets

P2Y12 receptor and cyclooxygenase (COX)

Marketed (2)

• short postimplantation dual antiplatelet therapy · National Institute of Cardiology, Warsaw, Poland · Cardiovascular
  A treatment regimen that combines two antiplatelet agents for a shortened duration following coronary stent implantation to prevent thrombosis while reducing bleeding risk.
• De-escalated Dual Antiplatelet Therapy · China National Center for Cardiovascular Diseases · Cardiovascular
  De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.

Phase 3 pipeline (1)

• Long DAPT · Federico II University · Cardiovascular
  Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention.